| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200-1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | IL4R; IL4RA; 582J2.1; Interleukin-4 receptor subunit alpha; IL-4 receptor subunit alpha; IL-4R subunit alpha; IL-4R-alpha; IL-4RA; CD antigen CD124 |
| Entrez GeneID | 3566; |
| WB Predicted band size | 90kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from human IL-4Rα around the non-phosphorylation site of Y497. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于IL-4Rα抗体的代表性文献及摘要概括：
---
1. **文献名称**：*Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis*
**作者**：Syed YY, et al.
**摘要**：综述了抗IL-4Rα单抗度普利尤单抗(Dupilumab)在中重度特应性皮炎中的疗效和安全性，通过阻断IL-4/IL-13信号通路显著改善患者皮肤症状及生活质量。
---
2. **文献名称**：*Targeting IL-4 Receptor Alpha for the Treatment of Asthma*
**作者**：Corren J, et al.
**摘要**：探讨IL-4Rα抗体在哮喘治疗中的作用机制，临床试验显示其可降低Th2型炎症反应，减少急性发作并改善肺功能。
---
3. **文献名称**：*IL-4Rα Inhibition in Eosinophilic Diseases: From Mechanism to Clinical Application*
**作者**：Bachert C, et al.
**摘要**：分析IL-4Rα抗体在嗜酸性粒细胞相关疾病(如慢性鼻窦炎伴鼻息肉)中的治疗潜力，通过抑制IL-4/IL-13通路减少组织嗜酸性浸润及症状恶化。
---
4. **文献名称**：*Structural Basis of IL-4 Receptor Signaling Modulation by Therapeutic Antibodies*
**作者**：Gauvreau GM, et al.
**摘要**：解析IL-4Rα抗体的结构生物学机制，揭示其如何竞争性结合受体并阻断下游JAK-STAT信号传导，为药物设计提供分子层面依据。
---
以上文献覆盖了IL-4Rα抗体在疾病治疗、机制研究及临床转化中的关键进展。
Interleukin-4 receptor alpha (IL-4Rα) is a critical component of the Type I and Type II interleukin-4 (IL-4) and interleukin-13 (IL-13) receptor complexes, playing a central role in Th2-mediated immune responses. It is implicated in the pathogenesis of several allergic and inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. IL-4Rα antibodies are monoclonal antibodies designed to block the interaction of IL-4 and IL-13 with their receptors, thereby inhibiting downstream signaling pathways (e.g., STAT6) that drive inflammation, tissue remodeling, and IgE production.
Dupilumab, the first FDA-approved IL-4Rα antibody (2017), has demonstrated efficacy in moderate-to-severe atopic dermatitis, asthma, and other Th2-associated conditions. By targeting IL-4Rα, these antibodies broadly suppress Th2 cytokines, offering a targeted therapeutic approach compared to traditional immunosuppressants. Clinical trials show significant improvements in symptom scores, exacerbation rates, and quality of life, with a favorable safety profile. Common side effects include injection-site reactions and conjunctivitis.
Ongoing research explores expanded applications in eosinophilic disorders, food allergies, and autoimmune diseases. The success of IL-4Rα antibodies underscores the importance of cytokine-receptor targeting in precision medicine, paving the way for next-generation biologics in immune dysregulation.
×
